Robert Jones

Robert Jones

Adjunct Faculty

BSc Guelph, PhD Tennessee

Research Interests

* Genetically engineered mouse models of cancer

* Molecular mechanisms of tumor recurrence

* Retinoblastoma (Rb) pathway in mitochondrial function and cancer

* Comparative genomics of breast and lung cancer


* Cell and molecular biology

* Cancer biology

* Pharmacology

* Laboratory methods for biomedical sciences

Selected Publications

Watson KL, Jones RA, Bruce A and Moorehead RA. The miR-200b/200a/429 cluster prevents metastasis and induces dormancy in a murine claudin-low mammary tumor cell line. Exp Cell Res. 369(1): 17-26. 2018.

Liu JC, Granieri L, Shrestha M, Wang D, Vorobieva I, Rubie E, Jones R, Ju Y, Pellecchia G, Jiang Z, Palmerini CA, Ben-David Y, Egan SE, Woodgett JR, Bader GD, Datti A and Zacksenhaus E. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Reports. 23(1): 112-126. 2018

Jones RA, Watson KA, Bruce A, Nersesian S, Kitz J, Moorehead RA. Re-expression of mir-200c suppresses proliferation, colony formation, and in vivo tumor growth of murine claudin-low mammary tumor cells. Oncotarget. 8: 23737-23749. 2017

Jones RA*, Robinson, T.J*, Liu J.C*, Shrestha M*, Voisin V*, Ju Y, Chung ED, Pellecchia G, Fell V, Bae S, Muthuswamy L, Datti A, Egan S.E, Jiang Z, Leone G, Bader G, Schimmer A and Zacksenhaus E. RB1-deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 126(10): 3739-3757. 2016 (* denotes co-first authors)

Franks SE, Jones RA, Briah R, Murray P, Moorehead RA. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes. 9(1):134. 2016

Franks SE, Briah R, Jones RA, Moorehead R.A. Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis. Oncotarget. 7(3):3297-316. 2016

Watson KL, Stalker L, Jones RA, Moorehead RA. High levels of dietary soy decrease mammary tumor latency and increase incidence in MTB-IGFIR transgenic mice. BMC Cancer. 6;15:37. 2015

Liu JC, Voisin V, Wang S, Wang DY, Jones RA, Datti A, Uehling D, Al-awar R, Egan SE, Bader GD, Tsao M, Mak TW, Zacksenhaus E. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med. 6(12):1542-60. 2014

Jones RA, Watson KL, Campbell CI, Moorehead RA. IGF-IR mediated mammary tumorigenesis is enhanced during pubertal development. PLoS One. 26;9(9):e108781. 2014

Jiang, Z., Deng, T., Jones, R., Li, H., Herschkowitz JI, Liu JC, Weigman VJ, Tsao MS, Lane TF, Perou CM, Zacksenhaus E. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest. 120(9):3296-309. 2010

Jones, RA., Petrik JJ, and Moorehead, RA. Pre-neoplastic changes persist after IGF-IR downregulation and tumor regression. Oncogene. 29(34):4779-86. 2010

Jones, RA., Campbell, CI., Wood, GA., Petrik JJ, and Moorehead, RA. Reversibility and recurrence of IGF-IR induced mammary tumors. Oncogene. 28(21): 2152-62. 2009

Jones, RA., Campbell, C.I., Petrik J.J, and Moorehead, R.A. Characterization of a primary mouse mammary tumor cell line reveals that cyclin D1 is regulated by IGF-IR. Mol Cancer Res. 6(5): 819-828. 2008

Jones, RA., Campbell, CI., Gunther, EJ., Chodosh, LA., Petrik JJ, Khokha, R. and Moorehead, RA. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 26(11): 1636-1644. 2007